Brigatinib is under clinical development by Millennium Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Brigatinib’s likelihood of approval (LoA) and phase transition for Ependymoma took place on 21 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 21 Oct 2022 increased Brigatinib’s Phase Transition Success Rate (PTSR) for Meningioma, increased PTSR for Neurofibromatoses Type II, and increased PTSR for Vestibular Schwannoma (Acoustic Neuroma).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Brigatinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Brigatinib overview

Brigatinib (AP-26113, Alunbrig, Evobrig) is an anti-neoplastic agent. It is formulated as film coated tablets, tablets for oral route of administration. Brigatinib is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib, or previously treated with crizotinib, and also as a first-line treatment option for adult  patients diagnosed with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.Alunbrig is indicated without conditions as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) and patients with ALK fusion gene-positive, advanced / recurrent solid tumors excluding non-small cell lung cancer.

It is also under development for the treatment of neurofibromatosis type 2 (NF2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas and ependymomas. It was also under development for anaplastic large cell lymphoma, diffuse large B cell lymphoma, metastatic brain tumors and inflammatory myofibroblastic tumor.

Millennium Pharmaceuticals overview

Millennium Pharmaceuticals is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. It is headquartered in Cambridge, Massachusetts, the US.

Quick View Brigatinib LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Brigatinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.